Hiroyu Hatano1. 1. Department of Medicine, University of California San Francisco, San Francisco, California 94110, USA. hhatano@php.ucsf.edu
Abstract
PURPOSE OF REVIEW: One of the potential barriers to current HIV cure strategies is the persistence of elevated levels of immune activation despite otherwise effective antiretroviral therapy (ART). The purpose of this review is to examine the relationship between immune activation and HIV persistence, and to review the novel therapeutic interventions that are currently being pursued to target immune activation in treated HIV disease. RECENT FINDINGS: Multiple groups have consistently observed that elevated levels of inflammation, immune activation, and immune dysfunction persist in ART-treated individuals, despite the successful suppression of plasma viremia. Increased immune activation may lead to viral persistence through multiple mechanisms. Several novel interventions aimed at decreasing persistent immune activation are being pursued and include studies aimed at decreasing low-level viral replication, approaches aimed at decreasing microbial translocation, interventions to treat co-infections, and therapies that directly target immune activation. SUMMARY: There appears to be a clear and consistent relationship between immune activation and viral persistence in treated HIV disease. Whether this relationship is causal or mediated through other mechanisms is still unknown. Small-scale, pathogenesis-oriented interventional studies are necessary to further evaluate this relationship and the effect of potential interventions.
PURPOSE OF REVIEW: One of the potential barriers to current HIV cure strategies is the persistence of elevated levels of immune activation despite otherwise effective antiretroviral therapy (ART). The purpose of this review is to examine the relationship between immune activation and HIV persistence, and to review the novel therapeutic interventions that are currently being pursued to target immune activation in treated HIV disease. RECENT FINDINGS: Multiple groups have consistently observed that elevated levels of inflammation, immune activation, and immune dysfunction persist in ART-treated individuals, despite the successful suppression of plasma viremia. Increased immune activation may lead to viral persistence through multiple mechanisms. Several novel interventions aimed at decreasing persistent immune activation are being pursued and include studies aimed at decreasing low-level viral replication, approaches aimed at decreasing microbial translocation, interventions to treat co-infections, and therapies that directly target immune activation. SUMMARY: There appears to be a clear and consistent relationship between immune activation and viral persistence in treated HIV disease. Whether this relationship is causal or mediated through other mechanisms is still unknown. Small-scale, pathogenesis-oriented interventional studies are necessary to further evaluate this relationship and the effect of potential interventions.
Authors: Timothy W Schacker; Phuong L Nguyen; Esteban Martinez; Cavan Reilly; Jose M Gatell; Andrzej Horban; Elzbieta Bakowska; Baiba Berzins; Remko van Leeuwen; Steven Wolinsky; Ashley T Haase; Robert L Murphy Journal: J Infect Dis Date: 2002-09-20 Impact factor: 5.226
Authors: K Sharma; B O Eltayeb; T A McGowan; S R Dunn; B Alzahabi; R Rohde; F N Ziyadeh; E J Lewis Journal: Am J Kidney Dis Date: 1999-11 Impact factor: 8.860
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks Journal: J Infect Dis Date: 2003-04-23 Impact factor: 5.226
Authors: Timothy W Schacker; Phuong L Nguyen; Gregory J Beilman; Steven Wolinsky; Matthew Larson; Cavan Reilly; Ashley T Haase Journal: J Clin Invest Date: 2002-10 Impact factor: 14.808
Authors: Martyn A French; Martin S King; Jean M Tschampa; Barbara A da Silva; Alan L Landay Journal: J Infect Dis Date: 2009-10-15 Impact factor: 5.226
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069
Authors: Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger Journal: J Virol Date: 2015-04-15 Impact factor: 5.103
Authors: Nikolas Itaru Wada; Lisa P Jacobson; Joseph B Margolick; Elizabeth Crabb Breen; Bernard Macatangay; Sudhir Penugonda; Otoniel Martínez-Maza; Jay H Bream Journal: AIDS Date: 2015-02-20 Impact factor: 4.177
Authors: Iart Luca Shytaj; Gabrielle Nickel; Eric Arts; Nicholas Farrell; Mauro Biffoni; Ranajit Pal; Hye Kyung Chung; Celia LaBranche; David Montefiori; Diego Vargas-Inchaustegui; Marjorie Robert-Guroff; Mark G Lewis; Jonah B Sacha; Anna Teresa Palamara; Andrea Savarino Journal: J Virol Date: 2015-05-13 Impact factor: 5.103
Authors: A Saez-Cirion; B Jacquelin; F Barré-Sinoussi; M Müller-Trutwin Journal: Philos Trans R Soc Lond B Biol Sci Date: 2014-05-12 Impact factor: 6.237